Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice

BACKGROUND: Acromegaly patients managed on Somatostatin receptor ligands (SRLs), the most common first-line pharmacotherapy for acromegaly, may still experience acromegaly symptoms such as headache, sweating, fatigue, soft tissue swelling, and joint pain, even those with normal IGF-1. Additionally,...

Descripción completa

Detalles Bibliográficos
Autores principales: Geer, Eliza B., Sisco, Jill, Adelman, Daphne T., Ludlam, William H., Haviv, Asi, Liu, Shuqian, Mathias, Susan D., Gelbaum, Dana, Shi, Lizheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393879/
https://www.ncbi.nlm.nih.gov/pubmed/32736547
http://dx.doi.org/10.1186/s12902-020-00595-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393879/
https://www.ncbi.nlm.nih.gov/pubmed/32736547
http://dx.doi.org/10.1186/s12902-020-00595-4

Ejemplares similares